Passage BIO annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Passage BIO Depreciation & Amortization Growth & History (PASG)
Passage BIO's depreciation and amortization was $728,000 for fiscal 2025.
View full Passage BIO company overviewPassage BIO annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $728,000 | −$2.4M | −76.37% |
| 2024 | 2024-12-31 | $3.1M | −$640,000 | −17.20% |
| 2023 | 2023-12-31 | $3.7M | $42,000 | +1.14% |
| 2022 | 2022-12-31 | $3.7M | $2.1M | +138.43% |
| 2021 | 2021-12-31 | $1.5M | $743,000 | +92.88% |
| 2020 | 2020-12-31 | $800,000 | $666,000 | +497.01% |
| 2019 | 2019-12-31 | $134,000 | — | — |
Passage BIO quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $25,000 | −$175,000 | −87.50% |
| Q1 2026 | 2026-03-31 | $129,000 | −$72,000 | −35.82% |
| Q4 2025 | 2025-12-31 | $177,000 | — | — |
| Q3 2025 | 2025-09-30 | $200,000 | −$600,000 | −75.00% |
| Q2 2025 | 2025-06-30 | $200,000 | −$600,000 | −75.00% |
| Q1 2025 | 2025-03-31 | $201,000 | −$605,000 | −75.06% |
| Q3 2024 | 2024-09-30 | $800,000 | −$200,000 | −20.00% |
| Q2 2024 | 2024-06-30 | $800,000 | −$200,000 | −20.00% |
| Q1 2024 | 2024-03-31 | $806,000 | −$172,000 | −17.59% |
| Q3 2023 | 2023-09-30 | $1.0M | $100,000 | +11.11% |
| Q2 2023 | 2023-06-30 | $1.0M | $100,000 | +11.11% |
| Q1 2023 | 2023-03-31 | $978,000 | $95,000 | +10.76% |
| Q3 2022 | 2022-09-30 | $900,000 | $440,000 | +95.65% |
| Q2 2022 | 2022-06-30 | $900,000 | $697,000 | +343.35% |
| Q1 2022 | 2022-03-31 | $883,000 | $672,000 | +318.48% |
| Q3 2021 | 2021-09-30 | $460,000 | $185,000 | +67.27% |
| Q2 2021 | 2021-06-30 | $203,000 | $5,000 | +2.53% |
| Q1 2021 | 2021-03-31 | $211,000 | $162,000 | +330.61% |
| Q3 2020 | 2020-09-30 | $275,000 | $234,000 | +570.73% |
| Q2 2020 | 2020-06-30 | $198,000 | $162,000 | +450.00% |
| Q1 2020 | 2020-03-31 | $49,000 | $37,000 | +308.33% |
| Q3 2019 | 2019-09-30 | $41,000 | — | — |
| Q2 2019 | 2019-06-30 | $36,000 | — | — |
| Q1 2019 | 2019-03-31 | $12,000 | — | — |
Passage BIO depreciation and amortization trends
Over the last five fiscal years, Passage BIO's depreciation and amortization decreased from $800,000 to $728,000, a change of −$72,000. The latest reported quarter, Q2 2026, shows $25,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Passage BIO source filings ↗